Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects

References

• De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598.
   PubMed Web of Science ®Google Scholar
• Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M. (1993). Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45:367–371.
   PubMed Web of Science ®Google Scholar
• Flouvat B, Delhotal-Landes B, Cournot A, Dellatolas F. (1993). Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 36:467–469.
   PubMed Web of Science ®Google Scholar
• Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T. (1999). CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552–561.
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. (2001). Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484–492.
   PubMed Web of Science ®Google Scholar
• Garnett WR. (1996). Lansoprazole: a proton pump inhibitor. Ann Pharmacother 30:1425–1436.
   PubMed Web of Science ®Google Scholar
• Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T. (2001). Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 15:793–803.
   PubMed Web of Science ®Google Scholar
• Hu YR, Qiao HL, Kan QC. (2004). Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. Acta Pharmacol Sin 25:986–990.
   PubMed Web of Science ®Google Scholar
• Hussein Z, Granneman GR, Mukherjee D, Samara E, Hogan DL, Koss MA, Isenberg JI. (1993). Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 36:391–398.
   PubMed Web of Science ®Google Scholar
• Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M. (1997). Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 52:391–396.
   PubMed Web of Science ®Google Scholar
• Miura M, Inoue K, Satoh S, Itoh Y, Kagaya H, Tada H, Tanaka Y, Habuchi T, Suzuki T. (2007). Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. Clin Drug Investig 27:251–258.
   PubMed Web of Science ®Google Scholar
• Niioka T, Miura M, Uno T, Yasui-Furukori N, Hayakari M, Tateishi T, Suzuki T. (2008). Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers. Eur J Clin Pharmacol 64:503–509.
   PubMed Web of Science ®Google Scholar
• Niioka T, Yasui-Furukori N, Uno T, Sugawara K, Kaneko S, Tateishi T. (2006). Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. Ther Drug Monit 28:321–325.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. (1996). Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805–816.
   PubMed Web of Science ®Google Scholar
• Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P. (1995). Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47:410–418.
   PubMed Web of Science ®Google Scholar
• Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ. (2006). Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 62:107–112.
   PubMed Web of Science ®Google Scholar
• Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A, Tateishi T. (2005). Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 59:302–309.
   PubMed Web of Science ®Google Scholar
• Sohn DR, Kwon JT, Kim HK, Ishizaki T. (1997). Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 61:574–582.
   PubMed Web of Science ®Google Scholar
• Song M, Gao X, Hang T, Wen A. (2008). Simultaneous determination of lansoprazole and its metabolites 5′-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal 48:1181–1186.
   PubMed Web of Science ®Google Scholar
• Wu GL, Zhou HL, Shentu JZ, He QJ, Yang B. (2008). Determination of lansoprazole in human plasma by rapid resolution liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. J Pharm Biomed Anal 48:1485–1489.
   PubMed Web of Science ®Google Scholar
• Yang LJ, Fan L, Liu ZQ, Mao YM, Guo D, Liu LH, Tan ZR, Peng L, Han CT, Hu DL, Wang D, Zhou HH. (2009). Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Eur J Clin Pharmacol 65:601–608.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. (2004). Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 44:1223–1229.
   PubMed Web of Science ®Google Scholar